NYSE - Delayed Quote USD

Eli Lilly and Company (LLY)

724.87 -7.33 (-1.00%)
At close: April 25 at 4:00 PM EDT
727.21 +2.34 (+0.32%)
Pre-Market: 5:15 AM EDT
Currency in USD All numbers in thousands
Download
Breakdown
TTM
12/31/2023
12/31/2022
12/31/2021
12/31/2020
Total Revenue
34,124,100.00
34,124,100.00
28,541,400.00
28,318,400.00
24,539,800.00
Cost of Revenue
7,082,200.00
7,082,200.00
6,629,800.00
7,312,800.00
5,483,300.00
Gross Profit
27,041,900.00
27,041,900.00
21,911,600.00
21,005,600.00
19,056,500.00
Operating Expense
16,254,600.00
16,254,600.00
13,258,300.00
13,072,600.00
11,955,100.00
Operating Income
10,787,300.00
10,787,300.00
8,653,300.00
7,933,000.00
7,101,400.00
Net Non Operating Interest Income Expense
-312,300.00
-312,300.00
-268,800.00
-314,400.00
-326,600.00
Other Income Expense
-3,920,400.00
-3,920,400.00
-1,578,100.00
-1,463,100.00
455,100.00
Pretax Income
6,554,600.00
6,554,600.00
6,806,400.00
6,155,500.00
7,229,900.00
Tax Provision
1,314,200.00
1,314,200.00
561,600.00
573,800.00
1,036,200.00
Net Income Common Stockholders
5,240,400.00
5,240,400.00
6,244,800.00
5,581,700.00
6,193,700.00
Diluted NI Available to Com Stockholders
5,240,400.00
5,240,400.00
6,244,800.00
5,581,700.00
6,193,700.00
Basic EPS
5.82
5.82
6.57
5.85
6.47
Diluted EPS
5.80
5.80
6.57
5.85
6.47
Basic Average Shares
900,181.00
900,181.00
950,182.00
953,653.00
956,590.00
Diluted Average Shares
903,284.00
903,284.00
950,182.00
953,653.00
956,590.00
Total Operating Income as Reported
6,457,900.00
--
--
--
--
Total Expenses
23,336,800.00
23,336,800.00
19,888,100.00
20,385,400.00
17,438,400.00
Net Income from Continuing & Discontinued Operation
5,240,400.00
5,240,400.00
6,244,800.00
5,581,700.00
6,193,700.00
Normalized Income
8,346,672.30
8,346,672.30
7,678,804.60
6,955,351.50
5,636,135.80
Interest Income
173,600.00
173,600.00
62,800.00
25,400.00
33,000.00
Interest Expense
485,900.00
485,900.00
331,600.00
339,800.00
359,600.00
Net Interest Income
-312,300.00
-312,300.00
-268,800.00
-314,400.00
-326,600.00
EBIT
7,040,500.00
7,040,500.00
7,138,000.00
6,495,300.00
7,589,500.00
EBITDA
8,567,800.00
8,567,800.00
8,660,500.00
8,042,900.00
8,913,400.00
Reconciled Cost of Revenue
7,082,200.00
7,082,200.00
6,629,800.00
7,312,800.00
5,483,300.00
Reconciled Depreciation
1,527,300.00
1,527,300.00
1,522,500.00
1,547,600.00
1,323,900.00
Net Income from Continuing Operation Net Minority Interest
5,240,400.00
5,240,400.00
6,244,800.00
5,581,700.00
6,193,700.00
Total Unusual Items Excluding Goodwill
-3,887,700.00
-3,887,700.00
-1,563,800.00
-1,514,500.00
650,600.00
Total Unusual Items
-3,887,700.00
-3,887,700.00
-1,563,800.00
-1,514,500.00
650,600.00
Normalized EBITDA
12,455,500.00
12,455,500.00
10,224,300.00
9,557,400.00
8,262,800.00
Tax Rate for Calcs
0.00
0.00
0.00
0.00
0.00
Tax Effect of Unusual Items
-781,427.70
-781,427.70
-129,795.40
-140,848.50
93,035.80
12/31/2020 - 6/1/1972

Upgrade to begin using 40 years of financial statements and get so much more.

Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.

Upgrade

Related Tickers

MRK Merck & Co., Inc.
130.72
+2.93%
 
ABBV AbbVie Inc.
167.29
-0.30%
 
PFE Pfizer Inc.
25.26
-3.84%
 
JNJ Johnson & Johnson
146.82
-1.15%
 
BMY Bristol-Myers Squibb Company
44.70
-8.51%
 
AMGN Amgen Inc.
269.38
-1.33%
 
BIIB Biogen Inc.
202.46
+0.23%
 
AZN AstraZeneca PLC
75.03
+5.38%
 
GILD Gilead Sciences, Inc.
65.27
-2.70%
 
NVS Novartis AG
99.06
+0.72%